MedTrace Logo

Assessment of Biomarkers for Recurrent HCV Infection Post-liver Transplantation

NCT00710801 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2011-09-15

No results posted yet for this study

Summary

The purpose of this study is to learn about how different immunosuppressant therapies impact on recurrent hepatitis C virus infection in the new liver after liver transplant. We will be evaluating if Cyclosporin A has a superior effect against recurrent Hepatitis C virus (HCV) infection than Tacrolimus.

Conditions

  • Hepatitis C Virus

Sponsors & Collaborators

  • Novartis

    collaborator INDUSTRY

  • University of Alberta

    lead OTHER

Principal Investigators

  • Andrew L Mason, MD · University of Alberta

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-05-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00710801 on ClinicalTrials.gov